Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer

Wang, Nan; Xu, Jingwen; Cao, Pikun; Li, Zhichao; Xue, Guoliang; Hu, Yanting; Zhang, Haitao; Han, Cuiping; Zhao, Wenhua; Yang, Xia; Wei, Zhigang; Ye, Xin

doi:10.1080/02656736.2023.2210269

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the destruction of lung tissue structure caused by ablation disrupts the local traction balance between bronchi and lung tissue. This disruption leads to air entering the cavity when bronchi with a high elastic coefficient are pulled away from the ablation area, thereby increasing the risk of complications such as pneumothorax, bronchopleural fistula, acute interstitial pneumonia, and intractable haemorrhage 24 .…”

Section: Discussionmentioning

confidence: 99%

Risk assessment of pneumothorax in colorectal lung metastases treated by percutaneous thermal ablation: A multicenter retrospective cohort study

Fan,

Xie,

Pang

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

Purpose: To evaluate the risk of pneumothorax in the percutaneous image-guided thermal ablation (IGTA) treatment of colorectal lung metastases (CRLM). Methods: Data regarding patients with CRLM treated with IGTA from five medical institutions in China from 2016 to 2023 were reviewed retrospectively. Pneumothorax and non-pneumothorax were compared using the Student’s t test、Chi-square test and Fisher’s exact test. Univariate logistic regression analysis was conducted to identify potential risk factors, followed by multivariate logistic regression (MLR) analysis to evaluate the predictors of pneumothorax. Interactions between variables were examined and used for model construction. Receiver operating characteristic (ROC) curves and nomograms were generated to assess the performance of the model. Results: A total of 254 patients with 376 CRLM underwent 299 ablation sessions. The incidence of pneumothorax was 45.5%. The adjusted MLR model, incorporating interaction terms, revealed that tumor number (odds ratio [OR]=8.34 [95% confidence interval [CI]: 1.37-50.64]), puncture depth (OR=0.53 [95%CI: 0.31-0.91]), pre-procedure radiotherapy (OR=3.66 [95%CI: 1.17-11.40]), peri-bronchial tumor (OR=2.32 [95%CI: 1.04-5.15]), and emphysema (OR=56.83 [95%CI: 8.42-383.57]) were significant predictive factors of pneumothorax (all P<0.05). The generated nomogram model demonstrated a significant prediction performance, with an area under the ROC curve of 0.800 (95%CI: 0.751-0.850). Conclusions: Pre-procedure radiotherapy, tumor number, peri-bronchial tumor, and emphysema were identified as risk factors for pneumothorax in the treatment of CRLM using percutaneous IGTA. Puncture depth was found to be a protective factor against pneumothorax.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk assessment of pneumothorax in colorectal lung metastases treated by percutaneous thermal ablation: A multicenter retrospective cohort study

Fan,

Xie,

Pang

et al. 2023

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

Hydrodissection technique for pain relief during peri-microwave ablation in patients with subpleural non-small cell lung cancers

Wang,

Xue,

Liu

et al. 2024

International Journal of Hyperthermia

View full text Add to dashboard Cite

Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging

Wang,

Xue,

Zheng

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundTo evaluate the safety and efficacy of percutaneous biopsy and microwave ablation (B + MWA) in patients with pulmonary nodules (PNs) who are receiving antithrombotic therapy by rivaroxaban as bridging therapy.MethodsThe study comprised 187 patients with PNs who underwent 187 B + MWA sessions from January 1, 2020, to December 31, 2021. The enrolled patients were divided into two groups: Group A, who received antithrombotic therapy five days before the procedure and received rivaroxaban as a bridging drug during hospitalization, and group B, who had no antithrombotic treatment. Information about the technical success rate, positive biopsy rate, complete ablative rate, and major complications were collected and analyzed.ResultsGroup A comprised 53 patients and group B comprised 134 patients. The technical success rate was 100% in both groups. The positive biopsy rates were 88.68% and 91.04%, respectively (p = 0.6211, X2 = 0.2443). In groups A and B, the complete ablative rates at 6, 12, and 24 months were 100.0% versus 99.25%, 96.23% versus 96.27%, and 88.68% versus 89.55%, respectively. There were no significant differences in bleeding and thrombotic complications between the two groups. No grade 5 complications occurred.ConclusionsIt is generally considered safe and effective that patients who are on antithrombotic therapy by rivaroxaban as bridging to undergo B + MWA for treating PNs.

show abstract

Early enlarging cavitation after percutaneous microwave ablation of primary lung cancer

Cited by 4 publications

References 35 publications

Risk assessment of pneumothorax in colorectal lung metastases treated by percutaneous thermal ablation: A multicenter retrospective cohort study

Risk assessment of pneumothorax in colorectal lung metastases treated by percutaneous thermal ablation: A multicenter retrospective cohort study

Hydrodissection technique for pain relief during peri-microwave ablation in patients with subpleural non-small cell lung cancers

Safety and efficacy of percutaneous biopsy and microwave ablation in patients with pulmonary nodules on antithrombotic therapy: A study with rivaroxaban bridging

Contact Info

Product

Resources

About